Registered title, quoted from ClinicalTrials.gov
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT04281641, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Participants agree to undergo a core needle biopsy for genomic testing and organoid drug sensitivity assay.
Inclusion criterion 7
Histologically proven diagnosis of breast cancer.
Inclusion criterion 8
Participants who received any investigational treatment within 4 weeks of study start.
Exclusion criterion 9
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (</=) 1.
Inclusion criterion 4
Any previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted agents, and antitumor vaccines) for cancer, or radiation therapy for cancer.
Exclusion criterion 2
Prior breast or non-breast malignancy within 5 years prior to study entry.
Exclusion criterion 3
Participants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus.
Exclusion criterion 10
Pregnancy or breast-feeding women.
Exclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04281641, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Female or male, presenting for the first time with operable breast cancer, who had not received any previous treatment for an invasive malignancy.
- Primary tumor greater than (>) 2 cm in diameter.
- Age ≥ 18 years and < 70 years.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (</=) 1.
- Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 55%
- Availability of tumor tissue specimen after surgery.
- Participants agree to undergo a core needle biopsy for genomic testing and organoid drug sensitivity assay.
- Histologically proven diagnosis of breast cancer.
- Patients have HER2-positive disease. HER2-positive disease was defined as follows: disease which overexpresses HER-2 by immunohistochemistry (IHC) 3+ and/or has HER2 amplification according to fluorescence in situ hybridization (FISH).
- Had hormonal receptors (ER and PgR) assessed.
- Signed informed consent.
- Able to comply with the protocol.
Exclusion Criteria:
- Metastatic disease (Stage IV) or bilateral breast cancer.
- Any previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted agents, and antitumor vaccines) for cancer, or radiation therapy for cancer.
- Prior breast or non-breast malignancy within 5 years prior to study entry.
- Inadequate bone marrow, renal, or liver function
- History or evidence of cardiovascular condition
- Severe, uncontrolled systemic disease
- Participants with poorly controlled diabetes or with evidence of clinically significant diabetic vascular complications.
- Pregnancy or breast-feeding women.
- Participants who received any investigational treatment within 4 weeks of study start.
- Participants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus.
- Current chronic daily treatment with corticosteroids (dose >10 mg methylprednisolone or equivalent [excluding inhaled steroids]).
- Known hypersensitivity to any of the study drugs or excipients
Quoted from ClinicalTrials.gov, NCT04281641, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT04281641, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.